Request PDF on ResearchGate | On Feb 1, , Hugo Donato and others published Tratamiento con eritropoyetina humana recombinante. Se demostró que el tratamiento con eritropoyetina humana recombinante (EPO rHu) en pacientes en diálisis es altamente efectivo en cuanto a la corrección de. Eritropoyetina humana recombinante para la anemia de la insuficiencia renal crónica en pacientes en prediálisis. This is not the most recent version of this.
|Published (Last):||22 January 2008|
|PDF File Size:||8.84 Mb|
|ePub File Size:||8.49 Mb|
|Price:||Free* [*Free Regsitration Required]|
Subscribe to receive email notifications whenever new articles are published. Population pharmacokinetics of darbepoetin alfa in healthy subjects. Redombinante of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients.
As previous studies showed that the kidneys contribute to Epo elimination in a very minor fashion 35 and residual kidney function in eritropoyetinaa more than three years on dialysis is most often negligible, it is not expected that renal elimination of Epo could be of any influence.
The study involved 24 hemodialysis patients, 10 patients with BEN and 14 with other kidney diseases, selected from 96 patients 40 BEN and 56 others who met the inclusion criteria. Main characteristics of the patients ACEI: Subscribe to free Drugs. The predose plasma level of erythropoietin Epo was subtracted from all postdose levels. El nivel de EPO en plasma recombnante a la dosis se sustrajo de todos los niveles que se obtuvieron tras administrarla.
Eritropoyetina Humana Recombinante
These findings need to be confirmed in a well-controlled study with a larger sample size in order to establish population pharmacokinetics of beta-Epo in BEN patients, to evaluate the effects of physiopathological factors on the disposition kinetics of beta-Epo and to find potential predictive factors for dosage individualization. Consult with your healthcare professional before taking any medication.
To view content sources and attributions, please refer to our editorial policy.
The authors declare that they have no conflicts of interest related to the contents of this article. Eur J Clin Pharmacol ; However, the influence of ESA pharmacokinetics on hematopoietic response has not been sufficiently investigated. Results of laboratory analyses in the examined individuals are given in Table 2.
Renal Injury from Drugs and Chemicals, third edition. Serum levels of iron, ferritin, transferrin saturation, C-reactive protein CRPalbumin, urea, creatinine, calcium, phosphorus and parathyroid hormone PTH were determined in each patient at the time of study. A total of 24 subjects was selected from the population of hemodialysis patients according to the following inclusion criteria: C reactive protein; Epo: For pharmacokinetic analysis the predose plasma level of Epo was subtracted from all postdose levels of Epo for each patient.
Eritropoyetina Humana Recombinante Delta –
The relevant pharmacokinetic parameters were calculated after noncompartmental pharmacokinetic analysis using Kinetica software Thermo Scientific, ver. J Biol Chem ; However, for protein and peptide drugs, dependency on active tissue uptake, binding to intra- and extravascular proteins can substantially increase the value of Vd. Results The study involved 24 hemodialysis patients, 10 patients with BEN and 14 with other kidney diseases, selected from 96 patients 40 BEN and 56 others who met the inclusion criteria.
Available for Android and iOS devices. Nephrol Dial Transplant ;19 Suppl 2: Erythropoietin Epo concentration was determined in all samples on the same day by chemiluminescent immunoassay for erythropoietin on an Immulite analyzer Siemens Healthcare Diagnostics.
Djukanovic Lj, Radovanovic Z. Available for Android and iOS devices. By clicking Subscribe, I agree to the Drugs.
Endemic nephropathy in Yugoslavia. Also, the difference in other pharmacokinetic parameters presented in Table 3 remained insignificant after adjustment. Comparison of the pharmacokinetics of recobinante given subcutaneously to hemodialysis patients with BEN or other kidney diseases non-BEN. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment.
Eritropoyetina Humana Recombinante –
Statistical analysis The results were expressed as mean values with standard deviations. Pharmacokinetics For pharmacokinetic analysis the predose plasma level of Epo was subtracted from all postdose levels of Epo for each patient.
Methods Study design and patients The prospective clinical study was performed according to good clinical practice and in accordance with the Declaration of Helsinki in three clinical centers. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you.